On April 25, 2019, Entasis Therapeutics Holdings Inc. announced that Andrew J. Staples and James N. Topper, M.D., Ph.D. notified the Board of Directors of their decision not to stand for re-election to the Board at the Company's 2019 annual meeting of stockholders. Each director will continue to serve as Class I Directors until the Annual Meeting. Mr. Staples will continue to serve as a member of the Audit Committee of the Board and Dr. Topper will continue to serve as Chair of the Compensation Committee of the Board until the Annual Meeting. Neither director’s decision not to stand for re-election was due to any disagreement with the Company. The Nominating and Corporate Governance Committee of the Board has nominated David Meek to stand for election as a Class I Director at the Annual Meeting. The Board has appointed Heather Preston to serve as a member of the Audit Committee and has appointed Gregory Norden to serve as Chair of the Compensation Committee, both upon completion of the Annual Meeting.